# Health Systems, Economic Evaluations, Quality of Life

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the intersection of health economics and quality of life assessment, with a particular emphasis on cost-effectiveness analysis, health utility measures such as EQ-5D and SF-36, quality-adjusted life years (QALY), health technology assessment, and preference-based measures for evaluating the economic impact of healthcare interventions. |
| Domain | Social Sciences |
| Field | Economics, Econometrics and Finance |
| OpenAlex ID | t10804 |
| Works | 1,104 |

## Topic papers all

Showing 15 of 1104.

- [The Cochrane Collaboration's tool for assessing risk of bias in randomised trials](https://scholariq.org/papers/the-cochrane-collaboration-s-tool-for-assessing-risk-of-bias-in-randomised/)
- [RoB 2: a revised tool for assessing risk of bias in randomised trials](https://scholariq.org/papers/rob-2-a-revised-tool-for-assessing-risk-of-bias-in-randomised-trials/)
- [GRADE: an emerging consensus on rating quality of evidence and strength of recommendations](https://scholariq.org/papers/grade-an-emerging-consensus-on-rating-quality-of-evidence-and-strength-of/)
- [Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019](https://scholariq.org/papers/global-burden-of-369-diseases-and-injuries-in-204-countries-and-territories-1990/)
- [ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions](https://scholariq.org/papers/robins-i-a-tool-for-assessing-risk-of-bias-in-non-randomised-studies-of/)
- [The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration](https://scholariq.org/papers/the-prisma-statement-for-reporting-systematic-reviews-and-meta-analyses-of-2/)
- [Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017](https://scholariq.org/papers/global-regional-and-national-incidence-prevalence-and-years-lived-with-4/)
- [A Proportional Hazards Model for the Subdistribution of a Competing Risk](https://scholariq.org/papers/a-proportional-hazards-model-for-the-subdistribution-of-a-competing-risk/)
- [2013 ESH/ESC Guidelines for the management of arterial hypertension](https://scholariq.org/papers/2013-esh-esc-guidelines-for-the-management-of-arterial-hypertension/)
- [K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification](https://scholariq.org/papers/k-doqi-clinical-practice-guidelines-for-chronic-kidney-disease-evaluation/)
- [AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both](https://scholariq.org/papers/amstar-2-a-critical-appraisal-tool-for-systematic-reviews-that-include/)
- [The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration](https://scholariq.org/papers/the-prisma-statement-for-reporting-systematic-reviews-and-meta-analyses-of-3/)
- [GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables](https://scholariq.org/papers/grade-guidelines-1-introduction-grade-evidence-profiles-and-summary-of-findings/)
- [Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies](https://scholariq.org/papers/strengthening-the-reporting-of-observational-studies-in-epidemiology-strobe-2/)
- [CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials](https://scholariq.org/papers/consort-2010-explanation-and-elaboration-updated-guidelines-for-reporting/)

## Topic primary papers

Showing 15 of 402.

- [ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions](https://scholariq.org/papers/robins-i-a-tool-for-assessing-risk-of-bias-in-non-randomised-studies-of/)
- [A Proportional Hazards Model for the Subdistribution of a Competing Risk](https://scholariq.org/papers/a-proportional-hazards-model-for-the-subdistribution-of-a-competing-risk/)
- [SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials](https://scholariq.org/papers/spirit-2013-explanation-and-elaboration-guidance-for-protocols-of-clinical/)
- [2021 ESC Guidelines on cardiovascular disease prevention in clinical practice](https://scholariq.org/papers/2021-esc-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice/)
- [Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines](https://scholariq.org/papers/cross-cultural-adaptation-of-health-related-quality-of-life-measures-literature/)
- [Measurement of health status](https://scholariq.org/papers/measurement-of-health-status/)
- [Measuring Health-Related Quality of Life](https://scholariq.org/papers/measuring-health-related-quality-of-life/)
- [The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration](https://scholariq.org/papers/the-prisma-statement-for-reporting-systematic-reviews-and-meta-analyses-of-5/)
- [GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology](https://scholariq.org/papers/grade-guidelines-a-new-series-of-articles-in-the-journal-of-clinical/)
- [Decision Modelling For Health Economic Evaluation](https://scholariq.org/papers/decision-modelling-for-health-economic-evaluation/)
- [Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses](https://scholariq.org/papers/recommendations-for-conduct-methodological-practices-and-reporting-of-cost/)
- [Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers](https://scholariq.org/papers/extensions-of-net-reclassification-improvement-calculations-to-measure/)
- [Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold](https://scholariq.org/papers/updating-cost-effectiveness-the-curious-resilience-of-the-50-000-per-qaly/)
- [A Critical Appraisal of the Quality of Quality-of-Life Measurements](https://scholariq.org/papers/a-critical-appraisal-of-the-quality-of-quality-of-life-measurements/)
- [Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force](https://scholariq.org/papers/consolidated-health-economic-evaluation-reporting-standards-cheers-explanation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.